Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)

30 Nov 2015
News

Jessica Merrill @Jessicaemerrill Jessica.merrill@informa.com

Executive Summary

The breakup fee for the Pfizer/Allergan merger would be $3.5bn in certain instances, but much lower, just $400m in expense reimbursement, if a party decides to terminate the deal due to an adverse change in law.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Related Companies

Related Deals

Pfizer, Allergan to combine in $160bn deal; merger scrapped due to tax law change

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical North America United States

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS057306

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS057306

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)

News

Executive Summary

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert